Imperative Care Secures $100M: Revolutionizing Stroke and Vascular Treatment
March 21, 2026, 9:36 pm
Imperative Care raised $100M, accelerating innovation in stroke and vascular care. This funding propels commercialization of successful thrombectomy systems—Zoom, Symphony, Prodigy—already used in over 78,000 global procedures. Crucially, it advances the Telos robotic platform. Telos, an endovascular robotic system, promises sub-millimeter precision for blood clot removal, aiming to standardize procedures and expand access to rural areas via potential telesurgery. New investors, including Elevage Medical Technologies and Perceptive Advisors, co-led the round. Dr. Evan Melrose joins the board. This investment marks a significant leap in treating thromboembolic disease and revolutionizing critical medical technology.
Imperative Care secured a monumental $100 million. This substantial financing round will propel the company forward. It will drive critical advancements in medical technology. The focus remains on thromboembolic disease. This condition involves dangerous blood clots. These clots devastate lives.
The oversubscribed convertible note financing round saw strong investor confidence. New investors led the charge. Elevage Medical Technologies and Perceptive Advisors were key players. Existing investor Catalio Capital Management also participated. Additional backing came from Longaeva Partners and Brown Advisory. Ally Bridge Group and Bain Capital Life Sciences reinforced their support. This diverse investment underscores market belief.
A significant strategic move accompanies the funding. Dr. Evan Melrose has joined Imperative Care’s Board of Directors. Dr. Melrose is CEO of Elevage Medical Technologies. His extensive background in medical technology investment is invaluable. His presence signals a strong commitment to market navigation. He brings decades of industry experience.
Imperative Care is not a newcomer. It is a commercial-stage powerhouse. Its existing product portfolio demonstrates proven success. The Zoom Stroke System, Symphony Thrombectomy System, and Prodigy Thrombectomy System are vital tools. These systems address blood clots in cerebral arteries and peripheral vasculature. They have been deployed widely. Over 78,000 procedures globally have utilized these technologies. This track record establishes market leadership.
The new capital will accelerate commercialization efforts. It will expand the reach of these life-saving technologies. Crucially, a significant portion targets future innovation. This includes the Telos robotic platform. Telos is an endovascular robotic system. It is currently under development.
The Telos platform represents the next frontier. It promises to revolutionize thrombectomy procedures. Current methods often rely on manual dexterity. Surgeons navigate complex blood vessels. Telos aims to replace this with robotic precision. Sub-millimeter accuracy becomes achievable. This level of mechanical control is unprecedented.
Precision offers profound benefits. It can reduce "first-pass" failure rates. Retrieving a clot successfully on the first attempt is paramount. Faster blood flow restoration minimizes brain damage. It improves patient outcomes dramatically. Telos ensures consistent, repeatable actions. This standardization is a game-changer.
Beyond precision, Telos offers broader access. Thromboembolic disease treatments are often centralized. Comprehensive stroke centers typically house neurointerventionalists. Patients in rural areas face significant barriers. They require airlift transport to specialized facilities. This delays critical treatment. Time is brain in stroke care.
The Telos platform can democratize thrombectomy. Its standardized movements make procedures easier to train. This could expand the pool of practitioners. The potential for telesurgery is immense. Remote operation of the robotic system becomes a possibility. A highly trained specialist could guide a procedure from afar. This would bring advanced stroke care to underserved regions. Geographic limitations would diminish. Every patient deserves timely intervention.
Thromboembolic disease remains a leading cause of long-term disability. Strokes are a primary example. Improving treatment accessibility directly impacts public health. Imperative Care’s mission is clear. It aims to provide critical technologies for patients at their most vulnerable moments. The $100 million investment reinforces this commitment. It ensures continued innovation across stroke, vascular, and beyond.
The medical technology market for thromboembolic disease is growing. The need for advanced solutions is urgent. Imperative Care's strategic vision aligns perfectly. Its blend of established products and cutting-edge robotics positions it uniquely. The company is set to drive the future of clot management. This investment fuels that vital journey. It signals a new era for stroke and vascular interventions.
Imperative Care secured a monumental $100 million. This substantial financing round will propel the company forward. It will drive critical advancements in medical technology. The focus remains on thromboembolic disease. This condition involves dangerous blood clots. These clots devastate lives.
The oversubscribed convertible note financing round saw strong investor confidence. New investors led the charge. Elevage Medical Technologies and Perceptive Advisors were key players. Existing investor Catalio Capital Management also participated. Additional backing came from Longaeva Partners and Brown Advisory. Ally Bridge Group and Bain Capital Life Sciences reinforced their support. This diverse investment underscores market belief.
A significant strategic move accompanies the funding. Dr. Evan Melrose has joined Imperative Care’s Board of Directors. Dr. Melrose is CEO of Elevage Medical Technologies. His extensive background in medical technology investment is invaluable. His presence signals a strong commitment to market navigation. He brings decades of industry experience.
Imperative Care is not a newcomer. It is a commercial-stage powerhouse. Its existing product portfolio demonstrates proven success. The Zoom Stroke System, Symphony Thrombectomy System, and Prodigy Thrombectomy System are vital tools. These systems address blood clots in cerebral arteries and peripheral vasculature. They have been deployed widely. Over 78,000 procedures globally have utilized these technologies. This track record establishes market leadership.
The new capital will accelerate commercialization efforts. It will expand the reach of these life-saving technologies. Crucially, a significant portion targets future innovation. This includes the Telos robotic platform. Telos is an endovascular robotic system. It is currently under development.
The Telos platform represents the next frontier. It promises to revolutionize thrombectomy procedures. Current methods often rely on manual dexterity. Surgeons navigate complex blood vessels. Telos aims to replace this with robotic precision. Sub-millimeter accuracy becomes achievable. This level of mechanical control is unprecedented.
Precision offers profound benefits. It can reduce "first-pass" failure rates. Retrieving a clot successfully on the first attempt is paramount. Faster blood flow restoration minimizes brain damage. It improves patient outcomes dramatically. Telos ensures consistent, repeatable actions. This standardization is a game-changer.
Beyond precision, Telos offers broader access. Thromboembolic disease treatments are often centralized. Comprehensive stroke centers typically house neurointerventionalists. Patients in rural areas face significant barriers. They require airlift transport to specialized facilities. This delays critical treatment. Time is brain in stroke care.
The Telos platform can democratize thrombectomy. Its standardized movements make procedures easier to train. This could expand the pool of practitioners. The potential for telesurgery is immense. Remote operation of the robotic system becomes a possibility. A highly trained specialist could guide a procedure from afar. This would bring advanced stroke care to underserved regions. Geographic limitations would diminish. Every patient deserves timely intervention.
Thromboembolic disease remains a leading cause of long-term disability. Strokes are a primary example. Improving treatment accessibility directly impacts public health. Imperative Care’s mission is clear. It aims to provide critical technologies for patients at their most vulnerable moments. The $100 million investment reinforces this commitment. It ensures continued innovation across stroke, vascular, and beyond.
The medical technology market for thromboembolic disease is growing. The need for advanced solutions is urgent. Imperative Care's strategic vision aligns perfectly. Its blend of established products and cutting-edge robotics positions it uniquely. The company is set to drive the future of clot management. This investment fuels that vital journey. It signals a new era for stroke and vascular interventions.